Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough

Table 5

MSC treatment on preclinical peritoneum fibrosis model.

References	Organism	Model	Treatment	MSC source	Timing	Quantity	Route	Outcome
[73]	Rat	CG	0.1% CG in 2 mL saline injected intraperitoneally	BM	30 minutes after CG injection	10^7 cells	Intraperitoneal	(i) Decreased infiltration of monocytes/macrophages; (ii) Reduced number of pSmad2 positive cells; (iii) Decreased number of α-SMA and FSP-1 positive cells; (iv) Decreased concentration of collagen I and collagen III

Outcomes are expressed compared to control groups (i.e. groups treated but not transplanted with MSCs) unless stated otherwise (α-SMA: α-Smooth Muscle Actin; BM: Bone Marrow; CG: Chlorhexidine Gluconate; FSP: Fibroblast Specific Protein; pSmad: phosphorylated Small Mothers Against Decapentaplegic Homolog).